Literature DB >> 8373822

Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor.

M Munch1, C W Heegaard, P A Andreasen.   

Abstract

The latent form of type-1 plasminogen activator inhibitor (PAI-1) acquires inhibitory activity by denaturation followed by refolding. We show here that the reactions of denatured/refolded PAI-1 with plasminogen activators are affected by low concentrations of SDS, which may remain after using SDS for denaturation. Without SDS, the active fraction of denatured/refolded PAI-1 comprised around 60%. Increasing SDS concentrations led to conversions to an inert form without inhibitory activity; then to a substrate form, that is being cleaved proteolytically in the reactive centre by the activators without complex formation, and finally to a second inert form. The first two conversions were associated with changes of the reactivity with monoclonal antibodies and of the thermal stability, respectively. Our results define clearly different interconvertible forms of denatured/refolded PAI-1, distinguish these from the latent and the reactive-centre-cleaved forms, and provide conditions for reproducibly producing reactive-centre-cleaved PAI-1 and PAI-1/activator complexes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8373822     DOI: 10.1016/0167-4838(93)90059-z

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.

Authors:  Jan K Jensen; Anders Malmendal; Birgit Schiøtt; Sune Skeldal; Katrine E Pedersen; Leyla Celik; Niels Chr Nielsen; Peter A Andreasen; Troels Wind
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

2.  Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.

Authors:  K W Rodenburg; L Kjoller; H H Petersen; P A Andreasen
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

3.  Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1.

Authors:  Stefan Verheyden; Alain Sillen; Ann Gils; Paul J Declerck; Yves Engelborghs
Journal:  Biophys J       Date:  2003-07       Impact factor: 4.033

4.  Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.

Authors:  Katrine E Pedersen; Anja P Einholm; Anni Christensen; Lotte Schack; Troels Wind; John M Kenney; Peter A Andreasen
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

5.  Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

Authors:  A Knoop; P A Andreasen; J A Andersen; S Hansen; A V Laenkholm; A C Simonsen; J Andersen; J Overgaard; C Rose
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

Review 6.  Functional stability of plasminogen activator inhibitor-1.

Authors:  Songul Yasar Yildiz; Pinar Kuru; Ebru Toksoy Oner; Mehmet Agirbasli
Journal:  ScientificWorldJournal       Date:  2014-10-15

7.  Plasminogen activator inhibitor-1 does not contribute to the pulmonary pathology induced by acute exposure to ozone.

Authors:  Hamza S Elkhidir; Jeremy B Richards; Kevin R Cromar; Cynthia S Bell; Roger E Price; Constance L Atkins; Chantal Y Spencer; Farhan Malik; Amy L Alexander; Katherine J Cockerill; Ikram U Haque; Richard A Johnston
Journal:  Physiol Rep       Date:  2016-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.